These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11642691)

  • 21. Overview of fluoroquinolone safety.
    Wolfson JS; Hooper DC
    Am J Med; 1991 Dec; 91(6A):153S-161S. PubMed ID: 1767803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interactions with fluoroquinolones.
    Stein GE
    Am J Med; 1991 Dec; 91(6A):81S-86S. PubMed ID: 1767807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of chemical structure on quinolone potency, spectrum and side effects.
    Percival A
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():1-8. PubMed ID: 1787126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
    Blondeau JM
    Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The quinolones: decades of development and use.
    Emmerson AM; Jones AM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():13-20. PubMed ID: 12702699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinolones: structure-activity relationships and future predictions.
    Tillotson GS
    J Med Microbiol; 1996 May; 44(5):320-4. PubMed ID: 8636945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.
    De Sarro A; De Sarro G
    Curr Med Chem; 2001 Mar; 8(4):371-84. PubMed ID: 11172695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug interactions with quinolone antibacterials.
    Brouwers JR
    Drug Saf; 1992; 7(4):268-81. PubMed ID: 1524699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.
    Lode H
    Chemotherapy; 2001; 47 Suppl 3():24-31; discussion 44-8. PubMed ID: 11549786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of fluoroquinolones in neutropenic patients--analysis of adverse effects.
    Rubinstein E; Potgieter P; Davey P; Norrby SR
    J Antimicrob Chemother; 1994 Jul; 34(1):7-19. PubMed ID: 7961217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks associated with the therapeutic use of fluoroquinolones.
    Stahlmann R; Lode HM
    Expert Opin Drug Saf; 2013 Jul; 12(4):497-505. PubMed ID: 23651367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of the quinolones.
    Stahlmann R
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():31-44. PubMed ID: 2286589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability of fluoroquinolone antibiotics. Past, present and future.
    Ball P; Tillotson G
    Drug Saf; 1995 Dec; 13(6):343-58. PubMed ID: 8652079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical evaluation of new quinolones as antituberculosis drugs].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 1999 Jan; 74(1):71-5. PubMed ID: 10067058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
    Aeschlimann JR; Kaatz GW; Rybak MJ
    J Antimicrob Chemother; 1999 Sep; 44(3):343-9. PubMed ID: 10511401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.